The effect of oestrogen implants on high density lipoproteins and its subfractions in women in their pre-mature menopause.
Oestrogen is recognized as having profound effects on lipid and lipoprotein levels. It is also considered as the agent protecting the pre-menopausal woman from arteriosclerotic cardiovascular disease. High density lipoprotein (HDL) has also been ascribed a protective role against the development of arteriosclerosis. The effect of natural oestrogen (17 beta-oestradiol) administered in the form of a subcutaneous pellet on concentrations of lipids and lipoproteins, particularly high density lipoproteins and its subfractions were determined in three young women with premature menopause. Plasma cholesterol, low density lipoprotein and very low density lipoprotein and very low density lipoprotein levels decreased following oestrogen implantation. High density lipoproteins and in particular subfraction 2 (density cut 1.063-1.125 gm/ml) and subfraction 3 (density cut 1.125-1.21 gm/ml) increased profoundly but there was a slight fall in the HDL 2/HDL 3 cholesterol ratio. The HDL/LDL cholesterol ratio increased from 0.21 to 0.46. A decrease in the urinary FSH levels paralleled these changes in the lipoprotein concentrations. Oestrogen administered in this form, unlike other oestrogen or mixed oestrogen--progestogen compounds is a definite modifier of arteriosclerotic risk, and as such could be given therapeutically in menopausal hypercholesterolemic females.
D000328:Adult; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D004343:Drug Implants; D004967:Estrogens / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D008593:Menopause; D008594:Menopause, Premature; D008875:Middle Aged
D008076:Cholesterol, HDL; D004343:Drug Implants; D004967:Estrogens; D008075:Lipoproteins, HDL; D002784:Cholesterol